Initializing terminal quote pipeline...

Command Palette

Search for a command to run...

Forward P/E

intermediate
7 min read
Updated 2026-07-13
Reviewed by SST Editorial
Forward P/E (or projected P/E) is a version of the price-to-earnings ratio that uses estimated future earnings rather than historical data. It is calculated by dividing the current stock price by the consensus Earnings Per Share (EPS) forecast for the next four quarters or next fiscal year. This allows investors to evaluate the stock based on its projected earnings growth rather than historical performance.

Key Takeaways

  • 01.Calculated as Current Stock Price / Estimated Future EPS.
  • 02.Reflects the company's growth trajectory: if forward P/E is lower than trailing P/E, earnings are expected to grow.
  • 03.Highly dependent on the accuracy of analyst estimates, which can be overly optimistic.
  • 04.Provides a better comparison for fast-growing companies whose past earnings are no longer representative.

Why it matters

Investing is forward-looking. Forward P/E helps determine if a stock that appears expensive on a trailing basis (due to low past earnings) is actually reasonably priced when factoring in near-term growth. It is a key metric used in institutional stock screening.

When it matters

It matters most during economic transitions or for high-growth sectors where earnings are expanding rapidly.

๐Ÿ“Š
Visual Reference: diagram

Comparing Trailing vs Forward P/E to show projected multiple compression from earnings expansion.

Interactive Tool: widget

Vary the future EPS forecast to observe the corresponding changes in the Forward P/E multiple.

Common Mistakes

Relying on unverified consensus estimates

Analyst consensus estimates are often slow to adjust to worsening macroeconomic conditions. A company's forward P/E may look attractive simply because analysts have not yet cut their earnings forecasts.

๐Ÿ“– Real-World Example: Growth multiple compression

A biotech firm traded at a high trailing P/E of 60. However, due to a newly approved drug, its earnings were projected to triple in the next fiscal year. As a result, its Forward P/E was only 20. The stock was actually reasonably valued relative to its near-term earnings power, which proved true when earnings rose and confirmed the multiple compression.

Further Reading